Abstract
To the Editor. —I was interested in reading an article by Sridama and co-workers 1 concerning HLA immunogenetic heterogeneity within patients with Graves' disease. These authors demonstrated that black Americans with Graves' disease showed an increased prevalence of HLA-DRw6 rather than the HLA-DR3 association found in white patients with Graves' disease. It is important to note that Angelini and co-workers2 had shown that at the genomic level of the polymorphisms of HLA-D subregions, using oligonucleotide probes, that HLA-DRw6 not only consists of at least two subtypes, but that these two subtypes cross-react with appropriate probes to the HLA-DR3 subregion. It is likely that this type of approach will have a more important predictive value in the study of the association of HLA and disease than the more traditional microcytotoxic assay approach. Of importance, however, is to realize that HLA-DRw6 and HLA-DR3 are not as distinct as the authors suggest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
